H-DL-Aad-OH

H-DL-Aad-OH is a racemic amino acid derivative presented as an amino acid hydrochloride salt-free format, bearing an amino group and a carboxylic acid functional group on the same chiral carbon framework. The "H-" designation indicates an unprotected amino functionality at the N-terminus, while the "-OH" denotes a free carboxylic acid suitable for salt formation, activation, and peptide coupling chemistry. The DL stereochemical label implies a 1:1 mixture of enantiomers, which influences stereochemical outcomes in downstream syntheses and can be used deliberately when racemic material is acceptable for screening or for conversion to single-enantiomer forms. The presence of primary amine and carboxylic acid groups enables straightforward derivatization, including protection strategies for peptide building-block workflows and activation routes for forming amide and related linkages.

1. Racemic Peptide Coupling

H-DL-Aad-OH supports peptide coupling chemistry in research contexts where racemic incorporation is acceptable, such as early-stage peptide library synthesis and method development. The unprotected primary amine and free carboxylic acid enable conversion into activated carboxyl derivatives or amide-forming intermediates that can be used with standard coupling reagents to assemble peptide bonds. The DL stereochemistry can be retained for screening studies or selectively resolved downstream to obtain enantiopure derivatives for stereochemical investigations. Downstream use commonly includes preparation of protected analogs that fit standard peptide synthesis cycles and generation of amide-linked fragments for structure-property exploration.

2. Unnatural Amino Acid Derivatization

H-DL-Aad-OH is suitable for amino acid derivatization workflows that transform the free amine into N-protected forms and the carboxyl group into esters or activated acids for controlled reactivity. The primary amine can be protected using common protecting-group strategies to suppress side reactions during functional group interconversions, while the carboxylic acid can be esterified to modulate solubility and coupling behavior. DL stereochemistry can be leveraged to generate racemic intermediate sets for SAR studies or to serve as a feedstock for stereoselective conversion to a single enantiomer. Resulting derivatives can be carried into peptide building block preparation, fragment coupling, or functionalized amino acid intermediate generation for synthetic organic chemistry campaigns.

3. Chiral Resolution Feedstock

H-DL-Aad-OH functions as a practical chiral synthetic intermediate when a racemate is intentionally introduced before stereochemical separation. The free carboxylic acid and primary amine provide handles for forming diastereomeric salts or derivatives with chiral reagents, enabling downstream isolation of enantiomerically enriched material. The stereochemical mixture is particularly relevant for process chemistry intermediate preparation where resolution steps may be integrated into a manufacturing route for chiral building blocks. Enantiopure products derived from this feedstock can then be converted into protected amino acid derivatives for stereochemically defined peptide construction and downstream chiral synthesis.

4. Chemical Biology Labeling

H-DL-Aad-OH can be incorporated into chemical biology and biomolecule modification strategies through amide bond formation after appropriate functional group activation and protection. The carboxyl group can be activated to enable coupling to amine-bearing targets, while the primary amine can be selectively protected or derivatized to introduce reporter handles such as linkers used in conjugation workflows. DL stereochemistry may be used when stereochemical uniformity is not required for binding-screening formats, or when racemic analog sets are used to map chemical recognition. Downstream derivatives prepared from this amino acid can serve as intermediates for labeled peptide fragments, conjugation-ready building blocks, and analytical probes that rely on stable amide linkages.

5. Pharmaceutical Intermediate Synthesis

H-DL-Aad-OH is applicable to pharmaceutical intermediate preparation where amino acid-based scaffolds require controlled protection and activation to support downstream synthesis. The unprotected amine and free acid can be converted into N-protected amino acid derivatives and carboxyl-activated intermediates that participate in amide formation with drug-like fragments. DL stereochemistry can be managed by either retaining racemic material for intermediate diversification or redirecting to a resolution step when enantiopure specifications are needed for later-stage stereochemical design. The resulting protected and activated forms align with common industrial fine chemical synthesis practices for constructing amide-rich molecules and peptide-like linkers used in medicinal chemistry programs.

6. Analytical Standards Development

H-DL-Aad-OH can serve as a reference material for analytical research and method development focused on amino acid derivatization and stereochemical analysis. The free amine and carboxylic acid enable derivatization into chromatographically responsive derivatives, supporting quantitation and identification in workflows that distinguish amino acid enantiomers or monitor coupling intermediates. DL stereochemistry makes it appropriate for calibration sets where racemic composition is expected, and it can also be converted into protected derivatives that better match analytical conditions used for peptide-related samples. Downstream use includes preparation of standards for LC-MS or chromatography method validation, as well as supporting characterization of protected amino acid intermediates generated during peptide synthesis and process chemistry development.

1. Novel Peptide-Based PD1 Immunomodulators Demonstrate Efficacy in Infectious Disease Vaccines and Therapeutics

2. Implications of ligand-receptor binding kinetics on GLP-1R signalling

3. Store-operated Ca2+ entry sustains the fertilization Ca2+ signal in pig eggs

4. Relatedness of antibodies to peptides containing homocitrulline or citrulline in patients with rheumatoid arthritis

5. Myotropic activity of allatostatins in tenebrionid beetles